Virtu Financial’s ProQR Therapeutics PRQR Stock Holding History

Virtu Financial’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31,158	Closed	-$83K	–	1907
2024 Q4	$83K	Buy	+31,158	New	+$98.9K	﹤0.01%	1061
2024 Q2	–	Sell	-25,943	Closed	-$59K	–	1772
2024 Q1	$59K	Sell	25,943 -8,961	-26%	-$19.2K	﹤0.01%	997
2023 Q4	$69K	Buy	+34,904	New	+$53.6K	0.01%	1117
2023 Q2	–	Sell	-94,564	Closed	-$201K	–	1933
2023 Q1	$201K	Buy	+94,564	New	+$289K	0.02%	751
2022 Q3	–	Sell	-61,425	Closed	-$48K	–	2126
2022 Q2	$48K	Buy	+61,425	New	+$45.8K	﹤0.01%	1130
2021 Q3	–	Sell	-13,883	Closed	-$94K	–	1860
2021 Q2	$94K	Buy	+13,883	New	+$89.5K	0.01%	1222
2017 Q4	–	Sell	-13,150	Closed	-$64K	–	2863
2017 Q3	$64K	Buy	+13,150	New	+$68.3K	﹤0.01%	2182

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Virtu Financial's PRQR Position: Q1 2025 in Review

Virtu Financial sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 31,158 shares — an estimated $83K sold.

Virtu Financial first reported a position in PRQR in Q3 2017 and held it in 7 quarters. The position peaked at $201K in Q1 2023. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

Virtu Financial reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
Virtu Financial sold 31,158 ProQR Therapeutics shares in Q1 2025, an estimated $83K.
Virtu Financial first reported a position in ProQR Therapeutics in Q3 2017 and held it in 7 quarters.
Virtu Financial's ProQR Therapeutics position peaked at $201K in Q1 2023.
65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.